EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
Alan Horwich(Institute of Cancer Research), Donna E. Hansel(The University of Texas MD Anderson Cancer Center), Silke Gillessen(Institute of Oncology Research), Pieter J. L. De Visschere(Ghent University Hospital), H.M. Bruins(Radboud University Nijmegen), Berardino De Bari(Inserm), Évanguelos Xylinas(NewYork–Presbyterian Hospital), Marek Babjuk(Charles University), Nicholas D. James(Royal Marsden NHS Foundation Trust), Daniel Castellano(Universidad Complutense de Madrid), Bogdan Geavlete(Saint John's Hospital), Paolo Gontero(Fondazione Ricerca Molinette), Alberto Briganti(University College London Hospitals NHS Foundation Trust), S. Hafeez(Institute of Cancer Research), Iris Brummelhuis(Radboud University Nijmegen), Tom Powles(Queen Mary University of London), W. DeBlok(University Medical Center Utrecht), Ananya Choudhury(University of Manchester), Jurgen J. Fütterer(Radboud University Nijmegen), Peter C. Black(University of British Columbia), Richard Cathomas(Kantonsspital Graubünden), Valérie Fonteyne(Ghent University Hospital), Karel Decaestecker(Ghent University Hospital), Theodorus van der Kwast(Erasmus MC), Stefano Fanti(Azienda USL di Bologna), Éva Compérat(Vienna General Hospital), Bernhard Grubmüller(Medical University of Vienna), Mark Frydenberg(Monash University), M. Bolla(Centre Hospitalier Universitaire de Grenoble), Joaquim Bellmunt(Dana-Farber Cancer Institute), Maria De Santis(Medical University of Vienna), Simon J. Crabb(University of Southampton), Shahrokh F. Shariat(Universitätszahnklinik Wien), Alison Birtle(University of Lancashire), Joost L. Boormans(Erasmus MC), Georgios Gakis(University Hospital in Halle), Steven MacLennan(University of Aberdeen), Juan Palou(Universitat Autònoma de Barcelona), Bernard H. Bochner(Memorial Sloan Kettering Cancer Center), Arturo Chiti(Vita-Salute San Raffaele University), Stéphane Culine(Hôpital Saint-Louis), Konstantinos Dimitropoulos(Aberdeen Royal Infirmary), Alberto Bossi(Institut Gustave Roussy), J.L. Domínguez-Escrig(Fundación Instituto Valenciano de Oncología), Aristotle Bamias(National and Kapodistrian University of Athens), Max M. Burger(Radboud University Nijmegen), T.J.H. Arends(Canisius-Wilhelmina Ziekenhuis), María J. Ribal(Hospital Clínic de Barcelona), N. Agarwal(University of Utah), Theo M. de Reijke(Amsterdam University Medical Centers)
Cited by 182
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k